Lytix Biopharma (LYTIX) Q1 2025 earnings summary

Executive summary

• Strengthened board and management with expertise in commercial drug development, immuno-oncology, and international business development to support late-stage development and commercialization.

• Lead drug candidate LTX-315 demonstrated strong phase II results in basal cell carcinoma, with an 86% reduction in tumor size and a 97% objective response rate, and positive results in late-stage melanoma.

• Expansion into early-stage melanoma (NeoLIPA) and deep-seated tumors (LTX-401), with ongoing and planned clinical trials.

• Focus on strategic partnerships, commercialization, and global expansion, supported by new leadership and board members.

• Organization ramping up for Phase III study and market entry following positive Phase II results in skin cancer.

Financial highlights

• Operating expenses declined as the ATLAS-IT-05 study nears completion, shifting cost base to high-priority initiatives.

• Cash and short-term investments at Q1 2025 totaled up to NOK 130.8 million, providing a strong liquidity position and runway well into 2026.

• Total liabilities increased to NOK 35 million at Q1 2025, mainly due to accrued expenses from clinical studies.

• Quarterly cash burn expected to be lower than 2024 levels as major trials conclude.

• Q1 2025 loss for the period was NOK 12.9 million, improved from NOK 18.2 million in Q1 2024.

Outlook and guidance

• Interim results from the NeoLIPA study in early-stage melanoma expected in Q3 2025; final/top-line results in H1/mid-2026.

• Immune response results and phase III program update for LTX-315 in basal cell carcinoma anticipated mid-2025.

• Phase I study for LTX-401 targeted to start in 2026, supported by positive regulatory feedback.

• Current cash position expected to fund operations well into 2026.